/PRNewswire/ Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced.
Study met all primary safety and efficacy endpoints for the Cordella PA Pressure Sensor System for the treatment of NYHA class III heart failure patients LISLE, Ill., May 23, 2022
Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study – Padovanews padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.
Amended study design provides immediate access and clinical benefits for all patients and becomes the first global IDE study for PA pressure-guided heart failure management LISLE